Actinium Pharmaceuticals, Inc. ATNM
1.35 USD -0.14 (-9.40%)
Regular-session close
1.35 0.00 0.00%
After hours · Nov 17, 4:00 PM ET
1.28 Day range 1.45
0.735 52-week range 1.72
- YTD
- -0.74%
- 1 year
- -6.90%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Actinium Pharmaceuticals, Maintains $4 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharmaceuticals (AMEX:ATNM) with a Buy and maintains $4 price target.
prnewswire.com Actinium Pharmaceuticals Provides Third Quarter 2026 Corporate Update Highlighting ATNM-400 and Other Business Progress Announced HER3 as the target of ATNM-400 and presented initial data from the first-in- human HERACT-PRO-1 Phase 1/2a study in metastatic castration-resistant prostate cancer (mCRPC) at EANM 2026…
prnewswire.com Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy Leading prostate cancer expert Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, to discuss unmet needs in metastatic castration-resistant prostate cancer (mCRPC) and the potential…
prnewswire.com Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy RADIANZ results will inform ATNM-400 clinical development beyond prostate cancer to patients with advanced HER3-expressing solid tumors in multiple cancers Builds on initial first-in-human clinical…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report…benzinga.com Actinium Pharma To Present First‑In‑Human Phase 1 Study Of ATNM‑400, HER3-Targeted, Non-PSMA Radiotherapy, In Metastatic Castration‑Resistant Prostate Cancer, At ESMO Congress 2026 First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy…
benzinga.com Why Is Actinium Pharmaceuticals Stock Gaining Tuesday? Actinium Pharmaceuticals shares jump 9% after positive Phase 1 ATNM-400 trial results in prostate cancer show early safety and retention.benzinga.com Actinium Pharmaceuticals Presents New Preclinical Data From Its ATNM-400 Across Non-Small Cell Lung Cancer At 39th Annual Congress Of European Association Of Nuclear Medicine Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX)…benzinga.com Actinium Pharmaceuticals To Present Data And Preclinical Results For ANTM-400 At The Congress Of The European Association Of Nuclear Medicine, October 17–21 First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMAPreclinical presentation to…
